Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor

Executive Summary

Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy

Related Content

Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Combo Drug Commercial Potential May Be Lowered By D.C. Court Ruling
Zetia/Zocor combo is Vytorin
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says
Merck/Schering Zetia Effects On Triglycerides, HDL-C Questioned In Review
Zetia angioedema labeling update
Merck/Schering Zetia Has 50% Combo Use; Statin Of Choice Is Lipitor 
Schering’s Rocky Succession: Former Mining Exec To Head CEO Search
Merck/Schering Zetia (Ezetimibe) Will Be Supported By Three Sales Forces



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts